*Myxoma virus* is a member of the family *Poxviridae* and the genus *Leporipoxvirus* ([@R1]). It causes a benign infection in American rabbits (*Sylvilagus* spp*.*) but is responsible for myxomatosis in the European rabbit (*Oryctolagus cuniculus*). This systemic and lethal infection is characterized by a large myxoma at the inoculation site, a leonine facies caused by edema, and numerous secondary myxomas ([@R2]).

Distinct myxoma virus (MYXV) strains from South America and California have been identified; virulence of California MSW strain is higher than that of South America strains in European rabbits ([@R3]). In contrast, the California MSD strain is reported to be less pathogenic ([@R3]) and has thus been used as a basis for the generation of vaccine strains on several occasions.

MYXV was introduced in France in 1952 as a means to control wild rabbit populations ([@R2]), and it has since spread widely throughout Europe. The strain used had been derived from a virulent South America strain ([@R4]) and has been called Lausanne since 1957 ([@R5]). Although MYXV was introduced to control wild rabbit populations, it rapidly spread to domestic rabbits, and by 1954, 30%--40% of the rabbit industry in France had been destroyed ([@R2]). Shope fibroma virus (SFV) was first used as a vaccine ([@R6]*,*[@R7]) but was only moderately effective. Limited trials were performed ([@R2]) by using an MSD-derived vaccine strain developed in California by Saito et al. ([@R8]), but this strain was later shown to cause myxomatosis symptoms in rabbits ([@R9]*,*[@R10]). Further attempts to attenuate the Saito strain were made ([@R9]). Some of the vaccine strains used throughout Europe today, such as Borghi ([@R11]) and MAV ([@R12]), are derived from the Saito strain.

In France, another attenuated vaccine was developed by Saurat et al. ([@R13]) in the École Nationale Vétérinaire de Toulouse virology laboratory. MYXV SG33 strain was obtained in 1977 by serial passages on a rabbit kidney cell line and chicken embryo cells at 33°C from an isolate obtained from a wild rabbit killed in the Toulouse area in 1973 ([@R13]). It has since been widely used as a vaccine against myxomatosis in rabbits in France and other countries in Europe.

Preliminary analyses of the SG33 genome showed a large deletion near the right end of the genome ([@R14]*,*[@R15]). Cavadini et al. recently performed a partial analysis of the SG33 sequence ([@R16]). They amplified and sequenced 200-bp to 10,000-bp fragments from 15 genomic locations, spanning 35 MYXV genes, and demonstrated that it was highly (97%--100% identity) similar to Lausanne. However, they reported somewhat lower similarities between both strains for M138L-M139R (GenBank accession no. HM104692) and M142R-M144R (GenBank accession no. HM104702) sequences, with 84% and 89% identity, respectively. They observed 100% identity between their M138L-M139R sequence and the only available MSD sequence, a partial sequence of M138L (GenBank accession no. AF030894) ([@R17]). We present the analysis of the genome sequence of MYXV SG33 vaccine strain, which confirms the presence of a large right-end deletion and shows evidence of a field recombination between a wild-type and a vaccine strain.

Materials and Methods
=====================

Cells and Viruses
-----------------

Rabbit kidney cells (RK13, ATCC CCL-37) were grown in Dulbecco modified Eagle medium (GIBCO-BRL-Invitrogen, Cergy-Pontoise, France) supplemented with 10% fetal calf serum (Eurobio, Les Ulis, France). Culture medium was supplemented with 100 units/mL penicillin and 100 µg/mL streptomycin. MYXV SG33 strain was propagated in RK13 cells grown in OptiMEM (GIBCO-BRL-Invitrogen) supplemented with 2% fetal calf serum, 100 units/mL penicillin, and 100 µg/mL streptomycin.

Genomic DNA Preparation
-----------------------

MYXV-infected RK13 cells were harvested and centrifuged. The cell pellet was homogenized in TL20 (20 mmol/L Tris, 150 mmol/L NaCl, 1 mmol/L EDTA; pH 8.6), disrupted in a Dounce tissue grinder, and centrifuged at 1,200 × *g* at 4°C for 10 minutes. The supernatant fluid was laid over an equal volume of a 36% sucrose cushion in TL20 and centrifuged at 200,000 × *g* for 2 hours in an SW 41 rotor at 4°C. The pellet was homogenized in TL20, laid over a 36% sucrose cushion, and recentrifuged. The new pellet was homogenized in TL20 and run into a linear 30%--65% sucrose gradient by centrifugation at 200,000 × *g* for 3 hours. The viral band was harvested and diluted in TL20 and then centrifuged at 130,000 × *g* for 1 hour. The pellet was homogenized in TL10 (1 mmol/L Tris, 150 mmol/L NaCl, 1 mmol/L EDTA; pH 8.6). After addition of 20% (vol/vol) of a 10% (wt/vol) sodium dodecyl sulfate solution, 20 µL of 10 µg/µL proteinase K of viral suspension, and 10% (vol/vol) of 20 mg/mL RNase A, the suspension was incubated at 50°C for 90 minutes with agitation. DNA was extracted by using a phenol/chloroform protocol and precipitated with 5 mol/L NaCl, 100% ethanol, rinsed with 70% ethanol, and resuspended in water.

DNA Sequencing and Sequence Analysis
------------------------------------

SG33 genomic DNA sequencing and assembly was performed at Beckman Coulter Genomics (Danvers, MA, USA) by using the Roche (Basel, Switzerland) 454 Life Sciences GS FLX Titanium pyrosequencing platform. The borders of the terminal inverted sequences (TIR) sequences were amplified and sequenced by using an internal primer (5′-ACGTCTACGTCCGACTGTCC-3′ for the left TIR, and 5′-AGTCGCGTGGAGAAATCAAT-3′ for the right TIR) and an external primer (5′-AATTTATAGCTCTTAAAAAAAAGTATAACC-3′) corresponding to the 30 first bp of Lausanne sequence (GenBank accession no. AF170726.2) ([@R18]).

Sequence genome alignments were performed by using BLAST ([@R19]) and DNA Strider version 1.4 ([@R20]). The complete SG33 sequence has been deposited in GenBank under accession no. GQ409969.

Results
=======

MYXV SG33 strain DNA was extracted from infected RK13 cells and sequenced. The generated contig was aligned to Lausanne strain genome sequence (GenBank accession no. AF170726.2) ([@R18]), for comparison. PCR amplification and sequencing of the most external 900 bp of each TIR showed 100% identity between both strains in these regions.

The genome of MYXV Lausanne strain was completely sequenced ([@R18]). Its 161.8 kbp encode 171 open reading frames (ORFs). Twelve of these ORFs are present in duplicate because of their localization in the TIRs of the genome. The left and right end regions of the genome (including the TIRs) mostly contain genes involved in the virulence of MYXV, whereas essential genes are found in the central part of the genome ([@R18]).

We determined SG33 genome to be 148,244 bp long, \>13.5 kbp shorter than that of Lausanne, which is consistent with our data indicating a large deletion at the right end of the genome ([@R14]*,*[@R15]). A deletion spans from the second half of M151R gene to the end of M-T1 (M001R). It was confirmed by PCR amplification of the region and resequencing (data not shown). The consequences of the deletion are the absence of 13 genes and the in-frame fusion of the truncated M151R and M001R ORFs (online Appendix Table, [www.cdc.gov/EID/content/17/4/633-appT.htm](http://www.cdc.gov/EID/content/17/4/633-appT.htm)).

M151R encodes Serp2, a serpin that specifically binds interleukin-1β--converting enzyme ([@R23]) and is involved in the pathogenesis of myxomatosis ([@R24]). The deletion would result in the putative translation of a Serp2 protein in which its 176 last aa are missing and replaced by the 80 C-terminal aa of M-T1 protein, a CC-chemokine inhibitor ([@R25]). It was shown that the reactive site loop of Serp2 corresponds to its last 40 aa ([@R26]). It is thus unlikely that Serp2 retains its enzymatic activity. As concerns M-T1, its structure and function rely on an N terminal signal sequence and 8 conserved cysteine residues spread throughout the protein ([@R27]). Thus, as with Serp2, the remaining M-T1 protein is unlikely to retain any activity. Furthermore, previous experiments showed that no protein could be specifically detected by an anti-Serp2 serum in SG33-infected cells ([@R23]), suggesting that the fusion protein is absent or unstable. A great proportion of the genes deleted in SG33 strain remain as a single copy in the left-end TIR (M002L, M003.1L, M003.2L, M004L, M005L, M006L, M007L, M008L, M008.1L), but M152R, M153R, M154R, and M156R are missing.

M152R encodes an atypical serpin, the deletion of which triggers an attenuation of virulence in rabbit, associated with the absence of secondary myxomas ([@R28]). M153R codes for a factor involved in MHCI and Fas-CD95 down-regulation. Its deletion induces a reduction of clinical signs and virulence in rabbits ([@R29]). M154R codes for a protein presenting 50% identity with M2L, a vaccinia virus gene that was shown to inhibit induction of NF-κB activation through an ERK2 pathway in virus-infected human embryonic kidney cells ([@R30]). Finally, M156R-encoded protein is a structural mimic of eukaryotic translation initiation factor eIF2α ([@R31]). Hence, all these genes seem to be involved in the virulence of MYXV, thus accounting for their combined deletion leading to a high attenuation of the strain.

Apart from this large deletion, SG33 genome presents other differences with Lausanne genome. Mutations in intergenic sequences are not discussed here. In contrast, we established a gene-by-gene comparison of Lausanne and SG33 strains. The genes presenting amino acid discrepancies are listed in the online Appendix Table.

Some of the differences observed with the genomic sequence of the Lausanne strain (online Appendix Table, M020L and M069L) have already been reported for other strains and were attributed to errors in the Lausanne genome sequence ([@R21]*,*[@R32]). They will not be further discussed.

M011L-encoded protein is involved in the regulation of apoptosis and is directed specifically to mitochondria by a short COOH-terminal region ([@R33]). In the SG33 genome, a substitution in M011L sequence leads to a non-sense codon and to the generation of 2 ORFs of 33 and 115 codons, respectively. The sequence surrounding the first AUG is 5′-UCGUCGAUGG-3′, which is partially divergent from KOZAK consensus (5′-gccRccAUGG-3′) ([@R34]) and thus consistent with the translation of the second ORF of the mRNA. The resulting protein should still have the ability to distribute in the mitochondria, because the targeting region is at the C-terminus of M11L ([@R33]). However, whether 1 or both of these polypeptides are actually expressed and functional remains to be clarified.

Among the other genes with major differences with regard to Lausanne, M077L is putatively lengthened by 23 N terminal amino acids because of the mutation of a stop codon upstream from the ATG ([Table](#T1){ref-type="table"}). Nevertheless, this potential additional coding sequence corresponds to the promoting region of M077L and might thus not be transcribed, let alone translated.

###### Myxoma virus genes with amino acids discrepancies between Lausanne and SG33 sequences\*

  ORF                 Position in genome†   Nucleotide changes or % identity‡   Amino acid changes or % identity§        
  ------------------- --------------------- ----------------------------------- ---------------------------------------- -------------------------------------------------------------------
  M005L               6383--4935            6369--4921                          A6351G                                   Silent
                                                                                C6286                                    R33Q
  M006L               7948--6422            7934--6408                          G6683A                                   Silent
                                                                                T6608G                                   E447D
  M011L¶              14125--13628                                                                                       
  M011bL                                    14110--14012                                                                 Initiates at M52
                                                                                A13890G                                  V28A
                                                                                A13857C                                  V39G
  M011aL                                    14569--14126                        G14103A                                  A8V
                                                                                G14024T                                  C34Stop
  M020L\#             20531--19197          20518--19181                        20379 GAG insertion                      Addition of L (aa 52)
  M030L               30037--29372          30024--29359                        T30011C                                  T10A
  M031R               30138--31316          30125--31303                        C30614T                                  A159V
  M034L               36864--33847          36851--33834                        T36186C                                  Y227C
  M044R               44157--46190          44144--46177                        A44593T                                  T146S
                                                                                A44596G                                  N147D
                                                                                G44940T                                  K261N
  M047R               48288--48962          48275--48949                        A48780G                                  T164A
  M049R               49312--50604          49299--50591                        G49777A                                  M155I
  M053R               52380--53159          52367--53146                        G53113A                                  D245N
  M054R               53183--54178          53170--54165                        97%                                      7 substitutions, 97%
  M058R               56201--56953          56188--56940                        C56404T                                  A68V
  M062R               58406--58879          58393--58866                        T58642C                                  I79T
  M064R               59631--60239          59617--60222                        60131 AGA insertion                      Addition of E (aa 163)
  M069L\#             66614--66081          66598--66083                        66101 T deletion                         6-aa addition
  M073R               70698--71279          70682--71263                        C70861T                                  A55V
  M076R               72702--75206          72686--75190                        100% (72686--73782) 95% (73783--75190)   11 substitutions, 98%
  M077L               75602--75174          75655--75158                        91%                                      8 substitutions, 94% identity
                                                                                C75619A T75620C                          Stop → C upstream of ATG, potential N-terminal 23 aa addition\*\*
  M078R               75608--76327          75592--76311                        94%                                      11 substitutions, 95%
  M079R               76327--76980          76311--76964                        96%                                      4 substitutions, 98%
  M080R               77017--79374          77001--79358                        95% (77001--77639) 99% (77640--79361)    6 substitutions, 99%
  M083L               82636--81779          82605--81763                        81958--81972 deletion                    218 YNVKA 222 deletion
  M085R               83302--84078          83271--84047                        C83976T                                  A225V
  M092L               91923--89965          91892--89934                        A90679C                                  S416A
  M095L               94089--92971          94058--92940                        A93326C A93328G                          S255P
  M096L               96252--94120          96221--94089                        C95947T                                  A103T
  M099L               100099--97397         100068--97366                       A98212G                                  I630T
  M111R               106301--107593        106270--107562                      T107143G                                 V281G
  M134R               125694--131693        125663--131662                      G130985A                                 S1773N
  M135R               131699--132232        131668--132201                      96%                                      8 substitutions in second half of protein
  M136R               132368--132904        132387--132929                      87%                                      KL insertion, 26 substitutions 83%
  M137R               132908--133837        132933--133862                      85%                                      48 substitutions, 84%
  M138L               134746--133877        134767--133898                      84%                                      53 substitutions, 81%††
  M139R               134806--135369        134818--135381                      91%                                      13 substitutions, 93%
  M140R               135375--137033        135387--137045                      90%                                      51 substitutions, 90%
  M141R               137069--137722        137089--137757                      80%                                      53 substitutions, 9 insertions/ deletions, 76%
  M142R               137731--138648        137768--138697                      89%                                      A306NITRI (C-terminal) 21 substitutions, 93%
  M143R               138665--139366        138701--139402                      90%                                      13 substitutions, 94%
  M144R               139411--140310        139452--140345                      84%                                      67 substitutions, EY deletion 77%
  M146R               140335--140658        140372--140695                      86%                                      15 substitutions, 85%
  M147R               140700--141563        140749--141609                      84%                                      31 substitutions, 89%
  M148R               141626--143650        141678--143799                      75%                                      217 substitutions, 67%
  M149R               143655--145124        143704--145173                      85%                                      63 substitutions, 87% ‡‡
  **M150R**           **145191--146672**    **145241--146713**                  **83%**                                  **96 substitutions, 80% ‡‡**
  **M151R**           **146684--147682**                                        **85% identity on 467 bp**               **84% identity on aa 1--157, C-terminal 176-aa deletion‡‡**
  **M001R**           **160190--160969**                                        **83% id on 244 bp**                     **87% identity on aa 181--260, N-terminal 180-aa deletion**
  **M151R-M001R§§**                         **146732--147439**                                                           

\***Boldface** indicates genes at the border of SG33 deletion. ORF, open reading frame. †Stop codon not included. ‡Nucleotide changes with position in Lausanne genome, or identity percentage if too many. §Amino acid changes with position in Lausanne ORF, or no. changes and identity percentage if too many. ¶ Apparition of a stop codon, leading to the potential translation of 2 polypeptides (M011aL and M011bL) from SG33 transcript. \# Identical to 6918 strain ([@R21]). \*\* Addition not probable in view of promoting region position. ††100% identity to 1,189 bp of MSD strain ([@R17]). ‡‡99.6% identity on 1,737 bp with MSW strain (discontinued sequences) ([@R22]). §§ Fusion of 2 partial ORFs as a result of deletion.

From a global point of view, when compared with the Lausanne genome, SG33 DNA exhibits a high degree of nucleotide similarity from M000.5L to half of M135R and at the end of the right TIR (M000.5R). In these regions, 108 genes encode proteins 100% identical to their Lausanne counterparts. Among these, 91 genes have nucleotide sequences that are 100% identical. In contrast, in the same regions, only 5 complete or partial ORFs (spanning from the second half of M076R to the first third of M080R) are \<97% identical to their Lausanne counterparts (online Appendix Table; Figure).

From M135R to M001R, and not taking the deletion into account, identity dropped to 75%--91% (online Appendix Table; Figure). We then compared SG33 sequence with the available partial sequences of California MYXV strains MSD and MSW. As described ([@R16]), SG33 is 100% identical to the only MSD sequence in GenBank, a partial sequence of M138L (GenBank accession no. AF030894) ([@R17]). Labudovic et al. ([@R22]) partially sequenced MSW strain using cloned *Eco*RI and *Sal*I fragments (GenBank accession nos. CC783373--CC783446 and CC799152--CC799159). The major difference between MSW and Lausanne strain is a duplication in the left TIR of 5 complete (M151R, M152R, M153R, M154R, and M156R) and 1 partial (M150R) ORFs from the right end of the genome, causing the partial deletion of M009L ([@R22]). As with Lausanne, comparison between SG33 and MSW sequences clearly shows 2 different regions in SG33 sequence ([Figure](#F1){ref-type="fig"}). From M002L to M134R, nucleotide identity between SG33 and MSW ranges from 70.9% to 95.2%, as is the case between Lausanne and MSW sequences ([@R22]). SG33 M076R and M080R, which were shown to be the more divergent from Lausanne in this region, showed identity within the same range (92.7% and 95.2% identity to MSW, respectively) and are thus not closer to MSW than to Lausanne. In contrast, SG33 and the available MSW sequences from M149R to M151R share 99.4% to 99.9% identity and present only 7 differences.

![Schematic comparison of SG33 nucleic acid similarities with Lausanne and California MSD/MSW myxoma virus (MYXV) strains. Nucleotide identities were calculated between SG33 and Lausanne open reading frames and between MSW available sequences and the corresponding SG33 sequences. Dotted lines, SG33 vs. Lausanne and MSD/MSW identity shifts. Gray box, SG33 deletion.](10-1146-F){#F1}

Discussion
==========

Analysis of SG33 genome sequence confirmed a 13.5-kbp deletion at the right end of the genome. Notably, only 1,045 bp of the right RIT remain in SG33 sequence. This finding suggests that such a short residual sequence is sufficient for a correct genome replication. In addition, comparison with databanks showed that SG33 seems to be a composite virus, resulting from a recombination between South America (Lausanne) and California (MSW/MSD) strains. The strain from which SG33 is derived was obtained from a rabbit killed in the Toulouse area in 1973. This isolate was injected into 2 rabbits in whom classical yet delayed myxomatosis developed. One rabbit survived, and the other died 34 days after infection, which indicates that this virus was attenuated to some degree, although the number of rabbits tested is not statistically relevant. Then, serial passages on a rabbit kidney cell line and chicken embryo cells at 33°C led to the strain named SG33 ([@R13]).

Although somewhat attenuated, the initial viral isolate had retained enough virulence to kill rabbits. Because several genes deleted in SG33 play a critical role in virus pathogenicity, it is unlikely that this deletion was present in the initial viral isolate and is more likely the result of in vitro adaptation. It is unfortunate that this initial viral isolate was lost (R. Py and J. Gelfi, unpub. data) because sequencing of this virus would be the only way to reach a definite conclusion on this point.

However, the question of the recombination remains open. No California strain has ever been handled in the virology laboratory of École Nationale Vétérinaire de Toulouse, where SG33 was obtained (R. Py, unpub. data). In contrast, before 1970, MSD-derived Saito strain ([@R8]*,*[@R35]) was used for some time as a vaccine in the rabbit industry in France ([@R2]). It has since been demonstrated that this strain is not completely attenuated and is responsible for myxomatosis symptoms in the rabbit ([@R9]*,*[@R10]). It is thus possible to assume that it could disseminate and infect wild rabbits.

During the same period, Lausanne-like strains were circulating in wild rabbits in the Toulouse area. For example, the Toulouse-1 strain, which was isolated from an infected rabbit in 1952 and deposited at the Collection Nationale de Cultures de Microorganismes at Pasteur Institute (CNCM I-1592), is close to Lausanne. M151R, M152R, and M153R are 99%--100% identical to their Lausanne counterparts ([@R26]*,*[@R28]*,*[@R29]). Thus, the most plausible explanation of the dual origin of SG33 is that the isolate used to generate it was itself the product of a field recombination between a virulent South America strain and a vaccine California strain. The fact that the only MSD sequence available shows 100% identity with the corresponding SG33 sequence (*16*; this work), strongly supports this hypothesis.

Other occurrences of recombination of poxvirus strains have been described. It was established that malignant rabbit virus is the result of a recombination between MYXV and SFV ([@R36]*,*[@R37]). Nevertheless, because it was isolated from tumors induced by an uncloned stock of SFV ([@R38]), the recombination event most likely happened in vitro. Similarly, Gershon et al. described genetic recombination between capripoxviruses during natural transmission of wild-type strains ([@R39]). However, SG33 sequence might be evidence of a recombination between vaccine and virulent poxvirus strains in the field.

These findings raise the issue of the use of insufficiently attenuated live viruses, especially when used as recombinant vaccines. It was shown that loss of transgene could occur in recombinant viruses obtained from in vitro co-infection of permissive cells with a live modified vaccinia Ankara--vectored influenza vaccine and a naturally occurring cowpox virus ([@R40]). As previously described, the MYXV Saito strain used before 1970 was not sufficiently attenuated and was thus potentially able to disseminate and recombine with circulating wild-type strains.

Since then, SG33 and Borghi vaccine strains have been widely used in France and in Europe, and no event of virulence recovery was ever reported, which suggests that the attenuation of these strains is stable. Nevertheless, a complete sequencing of MSD strain would give clearer insight into the origin of MYXV strains now used. However, this raises the need for better knowledge of the strains used to engineer recombinant viruses, particularly at a time when poxvirus-vectored vaccines against infectious diseases and cancer are being developed.
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